Search - tctmd.com

Displaying 101 - 120 of 153

Sort: Relevancy | Date

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

News Conference News TCT 2016

DES With Biodegradable Polymers Stand Up Well Against Durable-Polymer Stents in the Short Term

Todd Neale

October 30, 2016

News Conference News TCT 2016

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

Michael O'Riordan

October 29, 2016

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? No Cell Works. Genes are the Answer.

Presenter: Nabil Dib, Philippe Menasché, Marc S. Penn

October 15, 2015

Presentation TCT 2015

Gene Therapy for CHF

Presenter: Henricus J. Duckers, Bernard J. Gersh, Gary L. Schaer

October 14, 2015

News Conference News TCT 2015

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Yael L. Maxwell

October 14, 2015

News Conference News TCT 2015

FDA Speaker Outlines a Novel Vision for Device Regulation

October 13, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

News Conference News TCT 2015

Endovascular Therapies for Stroke Challenge the Adage ‘Time is Brain’

October 12, 2015

News Conference News TCT 2015

PREMIUM Trial: PFO Closure Primarily Benefits Migraine Patients With Aura

October 11, 2015

News Features TCT 2014

Thoughtful Insights at TCT: Many Questions Remain Around Treatment of Valvular Disease

Todd Neale

October 24, 2014

News Conference News TCT 2014

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Todd Neale

October 10, 2014

News Conference News TCT 2014

Long-term Outcomes Worse for Patients with Coronary Artery Aneurysm After DES Implantation

Yael L. Maxwell

September 19, 2014

Presentation TCT 2014

Gene Therapy to Reverse Remodel the Failing Heart: State of the Art

Presenter: Vasken Dilsizian, Sunil V. Rao, Jose P.S. Henriques, Krisztina Zsebo

September 15, 2014

News Conference News TCT 2014

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

September 15, 2014

News Conference News TCT 2014

Post-procedural Consent in STEMI Trials Debated

September 15, 2014

News Conference News TCT 2014

OPTIMIZE: Short-term DAPT Safe 2 Years After ZES Implantation

September 15, 2014

News Conference News TCT 2014

Keynote Address Focuses on Newer DES, Problematic Subgroups

September 15, 2014

News Conference News TCT 2014

Expert Discusses Potential Role for Platelet Function, Genetic Testing

September 15, 2014

News Conference News TCT 2013

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

November 04, 2013

Advertisement

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

DES With Biodegradable Polymers Stand Up Well Against Durable-Polymer Stents in the Short Term

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? No Cell Works. Genes are the Answer.

Gene Therapy for CHF

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

FDA Speaker Outlines a Novel Vision for Device Regulation

Discussion Highlights Merits, Limitations of Small Trials

Endovascular Therapies for Stroke Challenge the Adage ‘Time is Brain’

PREMIUM Trial: PFO Closure Primarily Benefits Migraine Patients With Aura

Thoughtful Insights at TCT: Many Questions Remain Around Treatment of Valvular Disease

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Long-term Outcomes Worse for Patients with Coronary Artery Aneurysm After DES Implantation

Gene Therapy to Reverse Remodel the Failing Heart: State of the Art

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

Post-procedural Consent in STEMI Trials Debated

OPTIMIZE: Short-term DAPT Safe 2 Years After ZES Implantation

Keynote Address Focuses on Newer DES, Problematic Subgroups

Expert Discusses Potential Role for Platelet Function, Genetic Testing

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content